Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,541 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
[Gemcitabine/cisplatin vs. MVAC. 5 year survival outcome of the phase III study of chemotherapy of advanced urothelial carcinoma in Germany].
Lehmann J, Retz M, Steiner G, Albers P, Jaeger E, Knuth A, Lippert C, Koser M, Stockamp K, Otto C, Melchior H, Fassmann C, Potratz C, Loch T, Derigs HG, Becker T, Kälble T, Piechota HJ, Hertle L, Weinknecht S, Weissbach L, Al-Mwalad M, Hamza A, Henss H, Brkovic D, Pomer S, Roloff J, Walz P, Muschter R, Tunn U, Winter E, Bub P, Kaldenbach U, Roth S, Brauers A, Jakse G, Richter AE, Wirth M, Hartlapp J, Van Ahlen H, Stöckle M. Lehmann J, et al. Among authors: wirth m. Urologe A. 2003 Aug;42(8):1074-86. doi: 10.1007/s00120-003-0317-4. Epub 2003 Apr 2. Urologe A. 2003. PMID: 14513232 Clinical Trial. German.
[Therapeutic options for hormone-refractory prostate cancer].
Miller K, Börgermann C, Thüroff J, Albers P, Wirth M. Miller K, et al. Among authors: wirth m. Urologe A. 2006 May;45(5):580, 582-5. doi: 10.1007/s00120-006-1048-0. Urologe A. 2006. PMID: 16710677 Review. German.
SWITCH II: Phase III randomized, sequential, open-label study to evaluate the efficacy and safety of sorafenib-pazopanib versus pazopanib-sorafenib in the treatment of advanced or metastatic renal cell carcinoma (AUO AN 33/11).
Retz M, Bedke J, Bögemann M, Grimm MO, Zimmermann U, Müller L, Leiber C, Teber D, Wirth M, Bolenz C, van Alphen R, De Santis M, Beeker A, Lehmann J, Indorf M, Frank M, Bokemeyer C, Gschwend JE. Retz M, et al. Among authors: wirth m. Eur J Cancer. 2019 Jan;107:37-45. doi: 10.1016/j.ejca.2018.11.001. Epub 2018 Dec 7. Eur J Cancer. 2019. PMID: 30529901 Clinical Trial.
[Early recognition of prostate carcinoma. Initial results of a prospective multicenter study in Germany. Project Group for Early Detection DGU-BDU Laboratory diagnosis Professional Circle].
Luboldt HJ, Altwein JE, Bichler KH, Czaja D, Hüsing J, Fornara P, Jöckel KH, Lübben G, Schalkhäuser K, Weissbach L, Wirth M, Rübben H. Luboldt HJ, et al. Among authors: wirth m. Urologe A. 1999 Mar;38(2):114-23. doi: 10.1007/s001200050253. Urologe A. 1999. PMID: 10231930 Clinical Trial. German.
1,541 results